Review Article
Amiodarone-Induced Cirrhosis of Liver: What Predicts Mortality?
Table 3
Prognostic indicators of 5-month survival.
| | Hazard ratio | 95% Confidence interval | |
| Age | 0.99 | (0.94–1.05) | 0.80 | Sex | 0.90 | (0.34–2.37) | 0.83 | Diabetes | 0.40 | (0.05–3.08) | 0.32 | HTN | 1.34 | (0.43–4.10) | 0.62 | Hyperlipidemia | 1.09 | (0.29–4.03) | 0.90 | CAD | 1.49 | (0.51–4.36) | 0.46 | CHF | 1.74 | (0.52–5.80) | 0.36 | >200 mg/ <200 mg Amiodarone dose given | 1.35 | (0.48–3.84) | 0.56 | Latency period | 1.12 | (0.90–1.38) | 0.33 | Cumulative dose | 1.001 | (0.999–1.003) | 0.09 | Prothrombin time | 1.04 | (0.97–1.11) | 0.36 | Bilirubin (micromole/liter) | 0.998 | (0.99–1.00) | 0.45 | AST | 1.003 | (1.001–1.006) | 0.03 | ALK P | 1.000 | (0.999–1.001) | 0.98 | Albumin | 0.99 | (0.91–1.09) | 0.89 | ALT | 1.002 | (0.999–1.005) | 0.21 | GGT | 1.000 | (0.998–1.002) | 0.87 |
|
|
Not all studies had data on all the variables.
|